Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai/Tokio Marine Launch Dementia Insurance Ahead of Leqembi Rollout
September 29, 2023
- Acoalan Misses Mark in PIII Preeclampsia Trial: Kyowa Kirin
September 29, 2023
- Pioneer Director Atsushi Kitamura Picked as Astellas CFO
September 29, 2023
- Entyvio Subcutaneous Form Approved in US: Takeda
September 29, 2023
- Shionogi’s Fragile X Syndrome Drug Gets Rare Pediatric Disease Tag in US
September 29, 2023
- Lilly Japan to Build New Manufacturing Facility, Eyes Mounjaro Supply Boost
September 28, 2023
- Mundipharma Files Anesthetic Med Anerem for New Indication in Japan
September 28, 2023
- Sawai’s Revlimid Generic Gets MDS Nod; December Listing Eyed
September 28, 2023
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- Pfizer Rolls Out Alopecia Areata Drug Litfulo in Japan
September 28, 2023
- Ono, Adimab Join Hands to Discover Antibody Drugs for Cancer
September 28, 2023
- Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
- Lilly’s Alzheimer’s Therapy Filed in Japan, Approval Eyed in 2024
September 27, 2023
- LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
September 27, 2023
- CureApp’s Hypertension Therapeutic App Shows Effects in Clinical Setting
September 27, 2023
- Viatris Japan to Go After Drugs in All Phases of Life Cycle, Group Consolidation by Year-End: Chief
September 26, 2023
- Oncolys, Cornell University to Partner in IIT of Telomelysin Combo
September 26, 2023
- Takeda Files Low-Dose Form of Ninlaro in Japan
September 25, 2023
- LTL Pharma Sees “G1” LLP Price Cuts as Business Opportunity: President
September 22, 2023
- Viatris Files Cystinosis Med in Japan
September 22, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…